Journal article
Mannitol and outcome in intracerebral hemorrhage: Propensity score and multivariable intensive blood pressure reduction in acute cerebral hemorrhage trial 2 results
X Wang, H Arima, J Yang, S Zhang, G Wu, M Woodward, P Muñoz-Venturelli, PM Lavados, C Stapf, T Robinson, E Heeley, C Delcourt, RI Lindley, M Parsons, J Chalmers, CS Anderson
Stroke | LIPPINCOTT WILLIAMS & WILKINS | Published : 2015
Abstract
Background and Purpose.Mannitol is often used to reduce cerebral edema in acute intracerebral hemorrhage but without strong supporting evidence of benefit. We aimed to determine the impact of mannitol on outcome among participants of the Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial (INTERACT2). Methods.INTERACT2 was an international, open, blinded end point, randomized controlled trial of 2839 patients with spontaneous intracerebral hemorrhage (<6 hours) and elevated systolic blood pressure allocated to intensive (target systolic blood pressure, <140 mm Hg within 1 hour) or guideline-recommended (target systolic blood pressure, <180 mm Hg) blood pressure.lowering tre..
View full abstractGrants
Awarded by National Health and Medical Research Council of Australia
Funding Acknowledgements
The second Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial study was supported by Program (571281) and Project (512402 and 1004170) grants from the National Health and Medical Research Council of Australia. The study was designed, conducted, analyzed, and interpreted by the investigators independent of sponsors.